


PHARMACEUTICAL 2020

SCYNEXIS INC Rank 268 of 362







PHARMACEUTICAL 2020

SCYNEXIS INC Rank 268 of 362



The relative strengths and weaknesses of SCYNEXIS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SCYNEXIS INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 57% points. The greatest weakness of SCYNEXIS INC is the variable Net Income, reducing the Economic Capital Ratio by 177% points.

The company's Economic Capital Ratio, given in the ranking table, is -402%, being 99% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	52,402
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,014
Liabilities, Non-Current	3,326
Other Assets	4,346
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	29,918
Other Net Income	-4,789
Property and Equipment	405
Research and Development	38,394
Revenues	121
Selling, General and Administrative Expense	10,648

Output Variable	Value in 1000 USD
Assets	57,153
Liabilities	44,258
Expenses	49,042
Stockholders Equity	12,895
Net Income	-53,710
Comprehensive Net Income	-53,710
Economic Capital Ratio	-402%